Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bod Australia Ltd ( (AU:BOD) ) has shared an announcement.
BOD Science Limited has finalized an Asset Sale Deed with Optimus Salvus Limited and the Aqua Phase inventors to sell its intellectual property rights, including soft gel/S3 clinical research, Aqua Phase data and IP, and CLIC Protein IP. The transaction is valued at AU$125,000, forgiving a £2M GBP debt, and a 5% equity interest in Optimus Salvus. This sale is part of a strategy to fulfill obligations under its Deed of Company Arrangement with Biortica Agrimed Limited, potentially providing financial relief and restructuring opportunities.
More about Bod Australia Ltd
BOD Science Limited is a company focused on cannabis drug development and product innovation. It aims to advance research and development and follows a deferred clinical trial pathway to commercialize and deliver premium, scientifically proven, and trusted products for both consumer and medical markets.
YTD Price Performance: 20.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$4.26M
Learn more about BOD stock on TipRanks’ Stock Analysis page.
